Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 11, 2004, Pages 2864-2869

  Meier Kriesche, Herwig Ulf ^a   Morris, Jonathan A ^b   Chu, Alice H ^b   Steffen, Bettina J ^b   Gotz, Vincent P ^b   Gordon, Robert D ^c   Kaplan, Bruce ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ProSanos Corporation   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Azathioprine; Elderly patients; Immunosuppression; Mycophenolate mofetil; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE DISEASE; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; ELDERLY CARE; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; RECIPIENT; REGISTER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

AGED; AZATHIOPRINE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; PROPORTIONAL HAZARDS MODELS;

EID: 8344268587     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh445     Document Type: Article

References (20)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
2. Foster CE, Philosophe B, Schweitzer EJ et al. A decade of experience with renal transplantation in African-Americans. Ann Surg 2002; 236: 794-804
3. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730
4. Tesi RJ, Elkhammas EA, Davies EA, Henry ML, Ferguson RM. Renal transplantation in older people. Lancet 1994; 343: 461-464
5. Schaubel D, Desmeules M, Mao Y, Fenton S. Survival experience among elderly end-stage renal disease patients: a controlled comparison of transplantation and dialysis. Transplantation 1995; 60: 1389-1394
6. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: US. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232
7. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325
8. Mathews TH. A blinded, long term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450-1454
9. Ismail N, Hakim RM, Helderman JH. Renal replacement therapies in the elderly. Part II. Renal transplantation. Am J Kidney Dis 1994; 23: 1-15
10. Hestin D, Frimat L, Hubert J, Renoult E, Huu TC, Kessler M. Renal transplantation in patients over sixty years of age. Clin Nephrol 1994; 42: 232-236
11. Jassal SV, Opelz G, Cole E. Transplantation in the elderly: a review. Geriatr Nephrol Urol 1997; 7: 157-165
12. Nyberg G, Nilsson B, Norden G, Karlberg I. Outcome of renal transplantation in patients over the age of 60: a case-control study. Nephrol Dial Transplant 1995; 10: 91-94
13. Meier-Kriesche HU, Ojo A, Hanson J et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000; 69: 885-889
14. Meier-Kriesche HU, Ojo AO, Arndorfer JA et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc 2001; 33: 1190-1191
15. Johnson DW, Nicol DL, Purdie DM et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation 2002; 73: 1158-1163
16. Hunsicker LG, Bennet LE. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int 1995; 52 [Suppl]: S120-S123
17. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68-73
18. /2). Transplantation 1994; 57: 857-859
19. Burke JF, Pirsch JD, Ramos EL et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994; 331: 358-363
20. Meier-Kriesche HU, Friedman G, Jacob M, Mulgaonkar S, Vaghela M, Kaplan B. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation 1999; 68: 1496-1502